Sally Van Doren

458 total citations
5 papers, 81 citations indexed

About

Sally Van Doren is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Sally Van Doren has authored 5 papers receiving a total of 81 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Infectious Diseases, 2 papers in Virology and 2 papers in Epidemiology. Recurrent topics in Sally Van Doren's work include HIV/AIDS drug development and treatment (3 papers), Hepatitis B Virus Studies (2 papers) and HIV Research and Treatment (2 papers). Sally Van Doren is often cited by papers focused on HIV/AIDS drug development and treatment (3 papers), Hepatitis B Virus Studies (2 papers) and HIV Research and Treatment (2 papers). Sally Van Doren collaborates with scholars based in United States. Sally Van Doren's co-authors include Carol Brosgart, Andrew Zolopa, David Katzenstein, Nancy S. Shulman, Dennis Israelski, Michael D. Miller, Robert W. Shafer, Douglas J. Passaro, K. Kleber and C. M. Kessler and has published in prestigious journals such as Blood, Gastroenterology and Journal of Hepatology.

In The Last Decade

Sally Van Doren

5 papers receiving 74 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sally Van Doren United States	4	70	63	17	8	7	5	81
Holly R. Hack United States	5	51 0.7×	41 0.7×	12 0.7×	5 0.6×	10 1.4×	8	71
Amj Wensing Netherlands	4	59 0.8×	73 1.2×	11 0.6×	5 0.6×	6 0.9×	8	81
Joseph Eron United States	3	39 0.6×	31 0.5×	17 1.0×	7 0.9×	6 0.9×	4	49
Marcelo Martins Argentina	3	61 0.9×	57 0.9×	9 0.5×	7 0.9×	3 0.4×	4	66
Liviana Della Torre Italy	5	54 0.8×	50 0.8×	23 1.4×	11 1.4×	2 0.3×	8	78
Rosemary Schluger United States	2	109 1.6×	96 1.5×	14 0.8×	18 2.3×	3 0.4×	3	125
Amalia Girón‐Callejas United States	7	83 1.2×	49 0.8×	28 1.6×	13 1.6×	3 0.4×	17	85
Xizi Deng China	8	100 1.4×	82 1.3×	41 2.4×	14 1.8×	9 1.3×	23	121
Josphat Kosgei United States	3	55 0.8×	44 0.7×	22 1.3×	3 0.4×	3 0.4×	9	64
Andy Burke United Kingdom	4	75 1.1×	67 1.1×	6 0.4×	3 0.4×	3 0.4×	5	84

Countries citing papers authored by Sally Van Doren

Since Specialization

Citations

This map shows the geographic impact of Sally Van Doren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sally Van Doren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sally Van Doren more than expected).

Fields of papers citing papers by Sally Van Doren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sally Van Doren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sally Van Doren. The network helps show where Sally Van Doren may publish in the future.

Co-authorship network of co-authors of Sally Van Doren

This figure shows the co-authorship network connecting the top 25 collaborators of Sally Van Doren. A scholar is included among the top collaborators of Sally Van Doren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sally Van Doren. Sally Van Doren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Mintz, Paul D., Anne T. Neff, Christopher D. Hillyer, et al.. (2004). Therapeutic Plasma Exchange (TPE) for Thrombotic Thrombocytopenic Purpura (TTP) Using Plasma Prepared with Photochemical Treatment (INTERCEPT Plasma).. Blood. 104(11). 838–838. 7 indexed citations

2.

Shiffman, M., Jenny Heathcote, Robert G. Gish, et al.. (2003). Long-term safety beyond 48 weeks of adefovir dipivoxil (ADV) 10 Mg once daily for chronic hepatitis B (CHB): An integrated analysis of two phase III studies. Gastroenterology. 124(4). A709–A709. 1 indexed citations

3.

Zoulim, Fabien, Christian Trépo, Thierry Poynard, et al.. (2003). Adefovir dipivoxil (ADV) for the treatment of patients with chronic hepatitis B (CHB) failing lamivudine (LAM) therapy. Journal of Hepatology. 38. 184–184. 4 indexed citations

4.

Shulman, Nancy S., Andrew Zolopa, Dennis Israelski, et al.. (2000). Rapid Communication: Efavirenz- and Adefovir Dipivoxil–Based Salvage Therapy in Highly Treatment-Experienced Patients: Clinical and Genotypic Predictors of Virologic Response. JAIDS Journal of Acquired Immune Deficiency Syndromes. 23(3). 221–226. 48 indexed citations

5.

Shulman, Nancy S., Andrew Zolopa, Douglas J. Passaro, et al.. (2000). Rapid Communication: Efavirenz- and Adefovir Dipivoxil–Based Salvage Therapy in Highly Treatment-Experienced Patients: Clinical and Genotypic Predictors of Virologic Response. JAIDS Journal of Acquired Immune Deficiency Syndromes. 23(3). 221–226. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact